Latest market price
15.61
+0.45+2.97%
OverviewShort InterestFilings
BHVNQT75Biohaven Ltd.·NYSE
15.61+2.97%
News
Up 3.0% — Biohaven Consensus Price Target Increased 10.16% to $24.48 (Fintel).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NAMS+1.74%$19.90RXRX-3.92%$3.68CLDX+2.31%$29.71IMNM+3.68%$20.31RCUS+5.94%$18.91PHVS+3.73%$34.78HRMY-2.35%$37.02XNCR+3.30%$30.64
Snapshot
Index—P/E—EPS (ttm)-3.86Insider Own32.08%Shs Outstand151.04MPerf Week2.09%
Market Cap2.29BForward P/E—EPS next Y-2.46Insider Trans0.00%Shs Float128.56MPerf Month20.35%
Enterprise Value2.42BPEG—EPS next Q0.07Short Float13.92%Perf Quarter14.53%
Income-543.00MP/S—EPS this Y—Short Ratio6.84Perf Half Y60.76%
Sales0.00P/B—EPS next Y—ROA-205.81%Short Interest17.90MPerf YTD38.26%
Book/sh-0.65P/C14.22EPS next 5Y—ROE—52W High18.24 -14.42%Perf Year-9.24%
Cash/sh1.07P/FCF—EPS past 3/5Y—ROIC-255.03%52W Low7.48 108.69%Perf 3Y-41.84%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility6.43% 6.76%Perf 5Y—
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)1.08Perf 10Y—
Dividend Ex-Date—Quick Ratio3.05Sales Y/Y TTM—Profit Margin0.00%RSI (14)61.39Recom2.40
Dividend Gr. 3/5Y—Current Ratio3.05EPS Q/Q47.56%SMA2018.40%Beta1.01Target Price24.67
Payout0.00%Debt/Eq—Sales Q/Q—SMA5014.04%Rel Volume0.63Prev Close15.16
Employees274LT Debt/Eq—EarningsMar 01SMA20027.38%Avg Volume3.20MPrice15.61
IPO DateSep 23, 2022Option/ShortYes / YesEPS/Sales Surpr.-9.79% —Net Debt/EBITDA—Volume2,016,828Change2.97%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-22-26ReiteratedRobert W. Baird$42 → $48
Sep-08-26DowngradeRBC CapitalOutperform → Sector Perform$22 → $19
Aug-28-26ReiteratedCanaccord GenuityBuy$21
Aug-26-26ReiteratedRaymond James$30
Aug-12-26ReiteratedMorgan StanleyOverweight$18 → $19
Jun-29-26ReiteratedNeedham$11
Jun-29-26DowngradeB of A SecuritiesNeutral → Underperform
May-13-26ReiteratedMorgan StanleyOverweight$26 → $18
Mar-04-26ReiteratedHC Wainwright & Co.Neutral$11 → $10
Mar-03-26ReiteratedLeerink PartnersOutperform$60 → $15
Latest News· Times ET
Nov-02-26
Nov-02-2610:49AM
Biohaven Consensus Price Target Increased 10.16% to $24.48Fintel
Oct-29-26
Oct-29-2604:02PM
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Resultsprnewswire.com
10:55AM
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Tradezacks.com
Oct-26-26
Oct-26-2607:30AM
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathyprnewswire.com
Oct-22-26
Oct-22-2603:00PM
Top US Stock Gainers and Losers for the Oct. 22, 2026 SessionChartMill
01:29PM
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Againbarrons.com
10:21AM
Biohaven Rebounds With FDA Review Date for Rare Disease Drugbenzinga.com
Oct-09-26
Oct-09-2609:12PM
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo
Oct-08-26
Oct-08-2612:11PM
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreementbenzinga.com
05:00AM
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Diseasegurufocus.com
Oct-02-26
Oct-02-2609:54AM
Roche’s AI lab; Biohaven’s pivotal pauseYahoo
Sep-29-26
Sep-29-2605:07AM
Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?Yahoo
Sep-28-26
Sep-28-2608:00AM
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026gurufocus.com
Sep-18-26
Sep-18-2608:48AM
Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.Yahoo
Sep-11-26
Sep-11-2606:28PM
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)prnewswire.com
Company

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
0000————
Cost of Goods Sold Incl. D&A1400————
Gross Profit-1-400————
Selling, General and Administrative Excl. Other971068963————
Research and Development429635796373————
Other Operating Expense
-3000————
Operating Income-524-745-885-436————
Interest Expense
0000————
Unusual Expense
————————
Non-Operating Income (Expense)-1783927————
Net Income Before Taxes-541-737-846-410————
Income Taxes011-1————
Consolidated Net Income-543-739-846-408————
Net Income From Continuing Operations-543-739-846-408————
Net Income-543-739-846-408————
EPS (Recurring)-3.86-6.86-9.28-5.73————
EPS (Basic, Before Extraordinaries)-3.86-6.86-9.28-5.73————
EPS (Diluted)-3.86-6.86-9.28-5.73————
EBITDA-533-727-838-403————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding1511089171————
Market Capitalization2,3571,2193,3993,039————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$19.66$16.30$12.95$9.60$6.24● Close Price0.00M8.29M16.57M24.86M33.14MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CHILDS JOHN WDirectorMar 04 '25Buy30.4561,1001,860,3542,323,971Mar 09
Gentile KimberlySVP, Clinical OperationsJan 05 '26Option Exercise0.003,7500101,513Jan 07
Buten MatthewChief Financial OfficerJan 05 '26Option Exercise0.004,2500198,246Jan 07
Coric VladChief Executive OfficerJan 05 '26Option Exercise0.0014,25001,811,398Jan 07
Car BruceChief Scientific OfficerJan 05 '26Option Exercise0.004,750010,096Jan 07
Clark George C.VP, Chief Accounting OfficerJan 05 '26Option Exercise0.002,500068,095Jan 07
Clark George C.VP, Chief Accounting OfficerNov 17 '25Buy8.5217,000144,77020,000Nov 18
Bailey GregoryDirectorNov 13 '25Buy7.50400,0003,000,0002,020,071Nov 17
CHILDS JOHN WDirectorNov 13 '25Buy7.503,333,33324,999,9985,653,904Nov 17
Coric VladChief Executive OfficerNov 13 '25Buy7.50666,6664,999,9961,195,275Nov 17
CHILDS JOHN WDirectorApr 22 '24Buy41.00268,29110,999,9314,096,512Mar 05
Car BruceChief Scientific OfficerJan 05 '25Option Exercise0.004,75007,133Jan 07
Gentile KimberlySVP, Clinical OperationsJan 05 '25Option Exercise0.003,750099,719Jan 07
Clark George C.VP, Chief Accounting OfficerJan 05 '25Option Exercise0.002,500066,168Jan 07
Buten MatthewChief Financial OfficerJan 05 '25Option Exercise0.004,2500196,013Jan 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.